Sernova Biotherapeutics Announces Departure of Chairperson
LONDON, Ontario and BOSTON – Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a pioneering company in regenerative medicine, revealed an important leadership change. The company specializes in developing its innovative Cell Pouch Bio-hybrid Organ, aimed at providing a functional cure for type 1 diabetes (T1D).
Chairperson Resignation Details
Ross Haghighat, who held the position of Chair, submitted his resignation, which was accepted by the Board of Directors. The board extends its gratitude to Ross for his dedicated service and leadership throughout his tenure. His contribution has been invaluable, and he leaves behind a legacy of trust and innovation.
Innovative Solutions in Regenerative Medicine
Sernova Biotherapeutics is at the forefront of developing regenerative medicine solutions aimed at transforming the treatment of chronic diseases like T1D. The company's Cell Pouch technology integrates human donor cells or stem-cell derived islet-like clusters. This collaboration with Evotec holds promise in creating Bio-hybrid Organs that may greatly enhance the quality of life for those suffering from such conditions.
What are Bio-hybrid Organs?
A Bio-hybrid Organ represents a novel approach in medical science, comprising non-biomaterials and living tissues combined to restore or improve organ function. This groundbreaking methodology is not only focused on T1D, but it also aims to address thyroid disorders, offering hope for more effective treatments in the future.
Looking Forward: The Future for Sernova Biotherapeutics
The current transition in leadership is an exciting time for Sernova Biotherapeutics. It positions the company to further pursue its ambitious goals in regenerative medicine and enhance its impact on patients' lives. As the company continues to innovate, the board and stakeholders remain optimistic about the direction in which Sernova is headed.
Contact Information for Inquiries
For more information, you can reach out to David Burke, VP of Investor Relations, at (917) 751-5713 or via email. Sernova is committed to maintaining transparency and communication with its investors and the public.
Frequently Asked Questions
What prompted the resignation of Ross Haghighat?
The resignation of Ross Haghighat was a decision accepted by the Board of Directors, marking a transition in Sernova's leadership.
What is Sernova Biotherapeutics focused on?
Sernova Biotherapeutics is dedicated to developing regenerative medicine with a focus on creating Bio-hybrid Organs for the treatment of type 1 diabetes and thyroid disorders.
How does the Cell Pouch technology work?
The Cell Pouch technology allows for the integration of living tissues and non-biomaterials to enhance organ function, representing a significant advancement in regenerative medicine.
Who is the current contact for investor relations at Sernova?
David Burke is the VP of Investor Relations and is available for inquiries related to company information.
What future plans does Sernova have following the leadership change?
Sernova aims to continue its innovative work in regenerative medicine and to strengthen its impact on treating chronic diseases as it moves forward with new leadership.
